In silico identification of potential Hsp90 inhibitors via ensemble docking, DFT and molecular dynamics simulations

References

• Abbasi, M., Sadeghi-Aliabadi, H., & Amanlou, M. (2017). Prediction of new Hsp90 inhibitors based on 3,4-isoxazolediamide scaffold using QSAR study, molecular docking and molecular dynamic simulation. Daru : Journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 25(1), 17 https://doi.org/10.1186/s40199-017-0182-0
   PubMedGoogle Scholar
• Abbasi, M., Sadeghi-Aliabadi., & Amanlou, M. (2018). 3D-QSAR, molecular docking, and molecular dynamic simulations for prediction of new Hsp90 inhibitors based on isoxazole scaffold. Journal of Biomolecular Structure & Dynamics, 36(6), 1463–1478. https://doi.org/10.1080/07391102.2017.1326319
   PubMed Web of Science ®Google Scholar
• Amaral, M., Kokh, D. B., Bomke, J., Wegener, A., Buchstaller, H. P., Eggenweiler, H. M., Matias, P., Sirrenberg, C., Wade, R. C., & Frech, M. (2017). Protein conformational flexibility modulates kinetics and thermodynamics of drug binding. Nature Communications, 8(1), 2276–2276. https://doi.org/10.1038/s41467-017-02258-w
   PubMedGoogle Scholar
• Barker, J. J., Barker, O., Boggio, R., Chauhan, V., Cheng, R. K., Corden, V., Courtney, S. M., Edwards, N., Falque, V. M., Fusar, F., Gardiner, M., Hamelin, E. M. N., Hesterkamp, T., Ichihara, O., Jones, R. S., Mather, O., Mercurio, C., Minucci, S., Montalbetti, C. A. G. N., … Yarnold, C. J. (2009). Fragment-based identification of Hsp90 inhibitors. ChemMedChem, 4(6), 963–966. https://doi.org/10.1002/cmdc.200900011
   PubMed Web of Science ®Google Scholar
• Barril, X., Beswick, M. C., Collier, A., Drysdale, M. J., Dymock, B. W., Fink, A., Grant, K., Howes, R., Jordan, A. M., Massey, A., Surgenor, A., Wayne, J., Workman, P., & Wright, L. (2006). 4-Amino derivatives of the Hsp90 inhibitor CCT018159. Bioorganic & Medicinal Chemistry Letters, 16(9), 2543–2548. https://doi.org/10.1016/j.bmcl.2006.01.099
   PubMed Web of Science ®Google Scholar
• Bhayye, S. S., Brahmachari, G., Nayek, N., Roy, S., & Roy, K. (2020). Target prioritization of novel substituted 5-aryl-2-oxo-/thioxo-2,3-dihydro-1H-benzo[6,7]chromeno[2,3-d]pyrimidine-4,6,11(5H)-triones as anticancer agents using in-silico approach. Journal of Biomolecular Structure & Dynamics, 38(5), 1415–1424. https://doi.org/10.1080/07391102.2019.1606735
   PubMed Web of Science ®Google Scholar
• Bosshard, H. R., Marti, D. N., & Jelesarov, I. (2004). Protein stabilization by salt bridges: Concepts, experimental approaches and clarification of some misunderstandings. Journal of Molecular Recognition: JMR, 17(1), 1–16. https://doi.org/10.1002/jmr.657
   PubMed Web of Science ®Google Scholar
• Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394–424. https://doi.org/10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Brough, P. A., Barril, X., Beswick, M., Dymock, B. W., Drysdale, M. J., Wright, L., Grant, K., Massey, A., Surgenor, A., & Workman, P. (2005). 3-(5-Chloro-2,4-dihydroxyphenyl)-pyrazole-4-carboxamides as inhibitors of the Hsp90 molecular chaperone. Bioorganic & Medicinal Chemistry Letters, 15(23), 5197–5201. https://doi.org/10.1016/j.bmcl.2005.08.091
   PubMed Web of Science ®Google Scholar
• Brough, P. A., Barril, X., Borgognoni, J., Chene, P., Davies, N. G. M., Davis, B., Drysdale, M. J., Dymock, B., Eccles, S. A., Garcia-Echeverria, C., Fromont, C., Hayes, A., Hubbard, R. E., Jordan, A. M., Jensen, M. R., Massey, A., Merrett, A., Padfield, A., Parsons, R., … Wright, L. (2009). Combining hit identification strategies: Fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. Journal of Medicinal Chemistry, 52(15), 4794–4809. https://doi.org/10.1021/jm900357y
   PubMed Web of Science ®Google Scholar
• Bruncko, M., Tahir, S. K., Song, X., Chen, J., Ding, H., Huth, J. R., Jin, S., Judge, R. A., Madar, D. J., Park, C. H., Park, C. M., Petros, A. M., Tse, C., Rosenberg, S. H., & Elmore, S. W. (2010). N-aryl-benzimidazolones as novel small molecule HSP90 inhibitors. Bioorganic & Medicinal Chemistry Letters, 20(24), 7503–7506. https://doi.org/10.1016/j.bmcl.2010.10.010
   PubMed Web of Science ®Google Scholar
• Calderwood, S. K., & Gong, J. (2016). Heat shock proteins promote cancer: It's a protection racket. Trends in Biochemical Sciences, 41(4), 311–323. https://doi.org/10.1016/j.tibs.2016.01.003
   PubMed Web of Science ®Google Scholar
• Calderwood, S. K., Khaleque, M. A., Sawyer, D. B., & Ciocca, D. R. (2006). Heat shock proteins in cancer: Chaperones of tumorigenesis. Trends in Biochemical Sciences, 31(3), 164–172. https://doi.org/10.1016/j.tibs.2006.01.006
   PubMed Web of Science ®Google Scholar
• Carlson, H. A. (2002). Protein flexibility and drug design: How to hit a moving target. Current Opinion in Chemical Biology, 6(4), 447–452. https://doi.org/10.1016/S1367-5931(02)00341-1
   PubMed Web of Science ®Google Scholar
• Casale, E., Amboldi, N., Brasca, M. G., Caronni, D., Colombo, N., Dalvit, C., Felder, E. R., Fogliatto, G., Galvani, A., Isacchi, A., Polucci, P., Riceputi, L., Sola, F., Visco, C., Zuccotto, F., & Casuscelli, F. (2014). Fragment-based hit discovery and structure-based optimization of aminotriazoloquinazolines as novel Hsp90 inhibitors. Bioorganic & Medicinal Chemistry, 22(15), 4135–4150. https://doi.org/10.1016/j.bmc.2014.05.056
   PubMed Web of Science ®Google Scholar
• Chen, D., Shen, A., Li, J., Shi, F., Chen, W., Ren, J., Liu, H., Xu, Y., Wang, X., Yang, X., Sun, Y., Yang, M., He, J., Wang, Y., Zhang, L., Huang, M., Geng, M., Xiong, B., & Shen, J. K. (2014). Discovery of potent N-(isoxazol-5-yl)amides as HSP90 inhibitors. European Journal of Medicinal Chemistry, 87, 765–781. https://doi.org/10.1016/j.ejmech.2014.09.065
   PubMed Web of Science ®Google Scholar
• Cho-Schultz, S., Patten, M. J., Huang, B., Elleraas, J., Gajiwala, K. S., Hickey, M. J., Wang, J., Mehta, P. P., Kang, P., Gehring, M. R., Kung, P. P., & Sutton, S. C. (2009). Solution-phase parallel synthesis of Hsp90 inhibitors. Journal of Combinatorial Chemistry, 11(5), 860–874. https://doi.org/10.1021/cc900056d
   PubMedGoogle Scholar
• Cui, W., Aouidate, A., Wang, S., Yu, Q., Li, Y., & Yuan, S. (2020). Discovering anti-cancer drugs via computational methods. Frontiers in Pharmacology, 11, 733. https://doi.org/10.3389/fphar.2020.00733
   PubMed Web of Science ®Google Scholar
• Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, 7, 42717. https://doi.org/10.1038/srep42717
   PubMed Web of Science ®Google Scholar
• Darden, T., York, D., & Pedersen, L. (1993). Particle mesh Ewald: An N log (N) method for Ewald sums in large systems. The Journal of Chemical Physics, 98(12), 10089–10092. https://doi.org/10.1063/1.464397
   Web of Science ®Google Scholar
• Durrant, J. D., & McCammon, J. A. (2011). Molecular dynamics simulations and drug discovery. BMC Biol, 9, 71–79. https://doi.org/10.1186/1741-7007-9-71
   PubMed Web of Science ®Google Scholar
• Dymock, B. W., Barril, X., Brough, P. A., Cansfield, J. E., Massey, A., McDonald, E., Hubbard, R. E., Surgenor, A., Roughley, S. D., Webb, P., Workman, P., Wright, L., & Drysdale, M. J. (2005). Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. Journal of Medicinal Chemistry, 48(13), 4212–4215. https://doi.org/10.1021/jm050355z
   PubMed Web of Science ®Google Scholar
• Ernst, J. T., Liu, M., Zuccola, H., Neubert, T., Beaumont, K., Turnbull, A., Kallel, A., Vought, B., & Stamos, D. (2014). Correlation between chemotype-dependent binding conformations of HSP90α/β and isoform selectivity-Implications for the structure-based design of HSP90α/β selective inhibitors for treating neurodegenerative diseases. Bioorganic & Medicinal Chemistry Letters, 24(1), 204–208. https://doi.org/10.1016/j.bmcl.2013.11.036
   PubMed Web of Science ®Google Scholar
• Ernst, J. T., Neubert, T., Liu, M., Sperry, S., Zuccola, H., Turnbull, A., Fleck, B., Kargo, W., Woody, L., Chiang, P., Tran, D., Chen, W., Snyder, P., Alcacio, T., Nezami, A., Reynolds, J., Alvi, K., Goulet, L., & Stamos, D. (2014). Identification of novel HSP90α/β isoform selective inhibitors using structure-based drug design. demonstration of potential utility in treating CNS disorders such as Huntington's disease. Journal of Medicinal Chemistry, 57(8), 3382–3400. https://doi.org/10.1021/jm500042s
   PubMed Web of Science ®Google Scholar
• Fadden, P., Huang, K. H., Veal, J. M., Steed, P. M., Barabasz, A. F., Foley, B., Hu, M., Partridge, J. M., Rice, J., Scott, A., Dubois, L. G., Freed, T. A., Silinski, M. A. R., Barta, T. E., Hughes, P. F., Ommen, A., Ma, W., Smith, E. D., Spangenberg, A. W., … Hall, S. E. (2010). Application of chemoproteomics to drug discovery: Identification of a clinical candidate targeting hsp90. Chemistry & Biology, 17(7), 686–694. https://doi.org/10.1016/j.chembiol.2010.04.015
   PubMed Web of Science ®Google Scholar
• Feldman, R. I., Mintzer, B., Zhu, D., Wu, J. M., Biroc, S. L., Yuan, S., Emayan, K., Chang, Z., Chen, D., Arnaiz, D. O., Bryant, J., Ge, X. S., Whitlow, M., Adler, M., Polokoff, M. A., Li, W.-W., Ferrer, M., Sato, T., Gu, J.-M., … Buckman, B. (2009). Potent triazolothione inhibitor of heat-shock protein-90. Chemical Biology & Drug Design, 74(1), 43–50. https://doi.org/10.1111/j.1747-0285.2009.00833.x
   PubMed Web of Science ®Google Scholar
• Fogarasi, G., Zhou, X., Taylor, P. W., & Pulay, P. (1992). The calculation of ab initio molecular geometries: Efficient optimization by natural internal coordinates and empirical correction by offwet forces. Journal of the American Chemical Society, 114(21), 8191–8201. https://doi.org/10.1021/ja00047a032
   Web of Science ®Google Scholar
• Gopalsamy, A., Shi, M., Golas, J., Vogan, E., Jacob, J., Johnson, M., Lee, F., Nilakantan, R., Petersen, R., Svenson, K., Chopra, R., Tam, M. S., Wen, Y., Ellingboe, J., Arndt, K., & Boschelli, F. (2008). Discovery of benzisoxazoles as potent inhibitors of chaperone heat shock protein 90. Journal of Medicinal Chemistry, 51(3), 373–375. https://doi.org/10.1021/jm701385c
   PubMed Web of Science ®Google Scholar
• Haggar, F. A., & Boushey, R. P. (2009). Colorectal cancer epidemiology: Incidence, mortality, survival, and risk factors. Clinics in Colon and Rectal Surgery, 22(4), 191–197. https://doi.org/10.1055/s-0029-1242458
   PubMedGoogle Scholar
• Hess, B., Bekker, H., Berendsen, H. J. C., & Fraaije, J. G. E. M. (1997). LINCS: A linear constraint solver for molecular simulations. Journal of Computational Chemistry, 18(12), 1463–1472. 987X(199709)18:123.0.CO;2-H https://doi.org/10.1002/(SICI)1096
   Web of Science ®Google Scholar
• Kabat, G. C., Matthews, C. E., Kamensky, V., Hollenbeck, A. R., & Rohan, T. E. (2015). Adherence to cancer prevention guidelines and cancer incidence, cancer mortality, and total mortality: A prospective cohort study. The American Journal of Clinical Nutrition, 101(3), 558–569. https://doi.org/10.3945/ajcn.114.094854
   PubMed Web of Science ®Google Scholar
• Kang, Y. N., & Stuckey, J. A. (2016). Structure of Heat Shock Protein 90 Bound to CS301. https://doi.org/10.2210/pdb4YKQ/pdb
   Google Scholar
• Kokh, D. B., Amaral, M., Bomke, J., Gradler, U., Musil, D., Buchstaller, H. P., Dreyer, M. K., Frech, M., Lowinski, M., Vallee, F., Bianciotto, M., Rak, A., & Wade, R. C. (2018). Estimation of drug-target residence times by τ-random acceleration molecular dynamics simulations. Journal of Chemical Theory and Computation, 14(7), 3859–3869. https://doi.org/10.1021/acs.jctc.8b00230
   PubMed Web of Science ®Google Scholar
• Kreusch, A., Han, S., Brinker, A., Zhou, V., Choi, H. S., He, Y., Lesley, S. A., Caldwell, J., & Gu, X. (2005). Crystal structures of human HSP90alpha-complexed with dihydroxyphenylpyrazoles. Bioorganic & Medicinal Chemistry Letters, 15(5), 1475–1478. https://doi.org/10.1016/j.bmcl.2004.12.087
   PubMed Web of Science ®Google Scholar
• Kung, P. P., Huang, B., Zhang, G., Zhou, J. Z., Wang, J., Digits, J. A., Skaptason, J., Yamazaki, S., Neul, D., Zientek, M., Elleraas, J., Mehta, P., Yin, M. J., Hickey, M. J., Gajiwala, K. S., Rodgers, C., Davies, J. F., & Gehring, M. R. (2010). Dihydroxyphenylisoindoline amides as orally bioavailable inhibitors of the heat shock protein 90 (hsp90) molecular chaperone. Journal of Medicinal Chemistry, 53(1), 499–503. https://doi.org/10.1021/jm901209q
   PubMed Web of Science ®Google Scholar
• Kung, P. P., Sinnema, P. J., Richardson, P., Hickey, M. J., Gajiwala, K. S., Wang, F., Huang, B., McClellan, G., Wang, J., Maegley, K., Bergqvist, S., Mehta, P. P., & Kania, R. (2011). Design strategies to target crystallographic waters applied to the Hsp90 molecular chaperone. Bioorganic & Medicinal Chemistry Letters, 21(12), 3557–3562. https://doi.org/10.1016/j.bmcl.2011.04.130
   PubMed Web of Science ®Google Scholar
• Li, J., Shi, F., Chen, D. Q., Cao, H. L., Xiong, B., & Shen, J. K. (2015). FS23 binds to the N-terminal domain of human Hsp90: A novel small inhibitor for Hsp90. Nuclear Science and Techniques, 26, 060502–060502. https://doi.org/10.13538/j.1001-8042/nst.26.060503
   Web of Science ®Google Scholar
• Li, J., Shi, F., Xiong, B., & He, J. H. (2019). Crystal structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor FS7. https://doi.org/10.2210/pdb5XRD/pdb
   Google Scholar
• Morris, G., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009). AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of Computational Chemistry, 30(16), 2785–2791. https://doi.org/10.1002/jcc.21256
   PubMed Web of Science ®Google Scholar
• Murray, C. W., Carr, M. G., Callaghan, O., Chessari, G., Congreve, M., Cowan, S., Coyle, J. E., Downham, R., Figueroa, E., Frederickson, M., Graham, B., McMenamin, R., O'Brien, M. A., Patel, S., Phillips, T. R., Williams, G., Woodhead, A. J., & Woolford, A. J.-A. (2010). Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency. Journal of Medicinal Chemistry, 53(16), 5942–5955. https://doi.org/10.1021/jm100059d
   PubMed Web of Science ®Google Scholar
• Neese, F. (2012). The ORCA program system. WIREs Computational Molecular Science, 2(1), 73–78. https://doi.org/10.1002/wcms.1503
   Google Scholar
• Neubert, T., Numa, M., Ernst, J., Clemens, J., Krenitsky, P., Liu, M., Fleck, B., Woody, L., Zuccola, H., & Stamos, D. (2015). Discovery of novel oxazepine and diazepine carboxamides as two new classes of heat shock protein 90 inhibitors. Bioorganic & Medicinal Chemistry Letters, 25(6), 1338–1342. https://doi.org/10.1016/j.bmcl.2015.01.023
   PubMed Web of Science ®Google Scholar
• Parrinello, M., & Rahman, A. (1981). Polymorphic transitions in single crystals: A new molecular dynamics method. Journal of Applied Physics, 52(12), 7182–7190. https://doi.org/10.1063/1.328693
   Web of Science ®Google Scholar
• Razzaghi-Asl, N., Ebadi, A., Shahabipour, S., & Gholamin, D. (2020). Identification of a potential SARS-CoV2 inhibitor via molecular dynamics simulations and amino acid decomposition analysis. Journal of Biomolecular Structure and Dynamics, https://doi.org/10.1080/07391102.2020.1797536
   Google Scholar
• Razzaghi-Asl, N., Mirzayi, S., Mahnam, K., & Sepehri, S. (2018). Identification of COX-2 inhibitors via structure-based virtual screening and molecular dynamics simulation. Journal of Molecular Graphics & Modelling, 83, 138–152. https://doi.org/10.1016/j.jmgm.2018.05.010
   PubMed Web of Science ®Google Scholar
• Roughley, S. D., & Hubbard, R. E. (2011). How well can fragments explore accessed chemical space? a case study from heat shock protein 90. Journal of Medicinal Chemistry, 54(12), 3989–4005. https://doi.org/10.1021/jm200350g
   PubMed Web of Science ®Google Scholar
• Salentin, S., Schreiber, S., Haupt, V. J., Adasme, M. F., & Schroeder, M. (2015). PLIP: Fully automated protein-ligand interaction profiler. Nucleic Acids Research, 43(W1), W443–W447. https://doi.org/10.1093/nar/gkv315
   PubMed Web of Science ®Google Scholar
• Sanner, M. (1999). Python: A programming language for software integration and development. Journal of Molecular Graphics & Modelling, 17(1), 57–61. PMID: 10660911
   PubMed Web of Science ®Google Scholar
• Sauvage, F., Messaoudi, S., Fattal, E., Barratt, G., & Vergnaud-Gauduchon, J. (2017). Heat shock proteins and cancer: How can nanomedicine be harnessed? Journal of Controlled Release : Official Journal of the Controlled Release Society, 248, 133–143. https://doi.org/10.1016/j.jconrel.2017.01.013
   PubMed Web of Science ®Google Scholar
• Schuetz, D. A., Richter, L., Amaral, M., Grandits, M., Gradler, U., Musil, D., Buchstaller, H. P., Eggenweiler, H. M., Frech, M., & Ecker, G. F. (2018). Ligand desolvation steers on-rate and impacts drug residence time of heat shock protein 90 (Hsp90) inhibitors. Journal of Medicinal Chemistry, 61(10), 4397–4411. https://doi.org/10.1021/acs.jmedchem.8b00080
   PubMed Web of Science ®Google Scholar
• Schuttelkopf, A. W., & Aalten, D. M. F. (2004). PRODRG: A tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallographica Section D Structural Biology, 60(8), 1355–1363. https://doi.org/10.1107/S0907444904011679
   Google Scholar
• Sharp, S. Y., Prodromou, C., Boxall, K., Powers, M. V., Holmes, J. L., Box, G., Matthews, T. P., Cheung, K. M. J., Kalusa, A., James, K., Hayes, A., Hardcastle, A., Dymock, B., Brough, P. A., Barril, X., Cansfield, J. E., Wright, L., Surgenor, A., Foloppe, N., … Workman, P. (2007). Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. Molecular Cancer Therapeutics, 6(4), 1198–1211. https://doi.org/10.1158/1535-7163
   PubMed Web of Science ®Google Scholar
• Sharp, S. Y., Roe, S. M., Kazlauskas, E., Čikotienė, I., Workman, P., Matulis, D., & Prodromou, C. (2012). Co-Crystalization and in vitro biological characterization of 5-aryl-4-(5-substituted-2-4-dihydroxyphenyl)-1,2,3-thiadiazole Hsp90 inhibitors. PLoS One, 7(9), e44642. https://doi.org/10.1371/journal.pone.0044642
   PubMed Web of Science ®Google Scholar
• Spoel, V. D. D., Lindahl, E., Hess, B., Groenhof, G., Mark, A. E., & Berendsen, H. J. (2005). GROMACS: Fast, flexible, and free. Journal of Computational Chemistry, 26(16), 1701–1718. https://doi.org/10.1002/jcc.20291
   PubMed Web of Science ®Google Scholar
• Stebbins, C. E., Russo, A. A., Schneider, C., Rosen, N., Hartl, F. U., & Pavletich, N. P. (1997). Crystal structure of an Hsp90-geldanamycin complex: Targeting of a protein chaperone by an antitumor agent. Cell, 89(2), 239–250. https://doi.org/10.1016/S0092-8674(00)80203-2
   PubMed Web of Science ®Google Scholar
• Taiyab, A., Sreedhar, A. S., & Rao, C. M. (2009). Hsp90 inhibitors, GA and 17AAG, lead to ER stress-induced apoptosis in rat histiocytoma. Biochemical Pharmacology, 78(2), 142–152. https://doi.org/10.1016/j.bcp.2009.04.001
   PubMed Web of Science ®Google Scholar
• Vallee, F., Carrez, C., Pilorge, F., Dupuy, A., Parent, A., Bertin, L., Thompson, F., Ferrari, P., Fassy, F., Lamberton, A., Thomas, A., Arrebola, R., Guerif, S., Rohaut, A., Certal, V., Ruxer, J. M., Delorme, C., Jouanen, A., Dumas, J., … Minoux, H. (2011). Tricyclic series of heat shock protein 90 (Hsp90) Inhibitors part I: Discovery of tricyclic imidazo[4,5-c]pyridines as potent inhibitors of the Hsp90 molecular chaperone. Journal of Medicinal Chemistry, 54(20), 7206–7219. https://doi.org/10.1021/jm200784m
   PubMed Web of Science ®Google Scholar
• Vallee, F., & Dupuy, A. (2017). Crystal structure of Hsp90 in complex with SAR567530. https://doi.org/10.2210/pdb5LR7/pdb
   Google Scholar
• Wainberg, Z. A., Anghel, A., Rogers, A. M., Desai, A. J., Kalous, O., Conklin, D., Ayala, R., O'Brien, N. A., Quadt, C., Akimov, M., Slamon, D. J., & Finn, R. S. (2013). Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer. Molecular Cancer Therapeutics, 12(4), 509–519. https://doi.org/10.1158/1535-7163
   PubMed Web of Science ®Google Scholar
• Woodhead, A. J., Angove, H., Carr, M. G., Chessari, G., Congreve, M., Coyle, J. E., Cosme, J., Graham, B., Day, P. J., Downham, R., Fazal, L., Feltell, R., Figueroa, E., Frederickson, M., Lewis, J., McMenamin, R., Murray, C. W., O'Brien, M. A., Parra, L., Patel, S., … Woolford, A. J. A. (2010). Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-Yl] methanone (at13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment-based drug design. Journal of Medicinal Chemistry, 53(16), 5956–5969. https://doi.org/10.1021/jm100060b
   PubMed Web of Science ®Google Scholar
• Wu, S., Zhu, W., Thompson, P., & Hannun, Y. A. (2018). Evaluating intrinsic and non-intrinsic cancer risk factors. Nature Communications, 9(1), 3490 https://doi.org/10.1038/s41467-018-05467-z
   PubMed Web of Science ®Google Scholar
• Yoshimura, C., Yamashita, S., Oshiumi, H., Uno, T., Kawai, Y., Chong, K. T., Kodama, Y., Kitade, M., & Ohkubo, S. (2015). Evolution of highly selective hsp90 inhibitors by structure and thermodynamics guided design. https://doi.org/10.2210/pdb3wq9/pdb
   Google Scholar
• Yun, C. W., Kim, H. J., Lim, J. H., & Lee, S. H. (2019). Heat shock proteins: Agents of cancer development and therapeutic targets in anti-cancer therapy. Cells, 9(1), 60. https://doi.org/10.3390/cells9010060
   PubMed Web of Science ®Google Scholar